Foy K - Search Results

1

An overview of the unique challenges facing African-American breast cancer survivors.

Husain M, Nolan TS, Foy K, Reinbolt R, Grenade C, Lustberg M. Husain M, et al. Among authors: foy k. Support Care Cancer. 2019 Mar;27(3):729-743. doi: 10.1007/s00520-018-4545-y. Epub 2018 Nov 20. Support Care Cancer. 2019. PMID: 30460398 Review.

2

Disparities in breast cancer tumor characteristics, treatment, time to treatment, and survival probability among African American and white women.

Foy KC, Fisher JL, Lustberg MB, Gray DM, DeGraffinreid CR, Paskett ED. Foy KC, et al. NPJ Breast Cancer. 2018 Mar 20;4:7. doi: 10.1038/s41523-018-0059-5. eCollection 2018. NPJ Breast Cancer. 2018. PMID: 29582015 Free PMC article.

3

Cancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics.

Miller MJ, Foy KC, Kaumaya PT. Miller MJ, et al. Discov Med. 2013 Mar;15(82):166-76. Discov Med. 2013. PMID: 23545045 Free article. Review.

4

Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo.

Foy KC, Liu Z, Phillips G, Miller M, Kaumaya PT. Foy KC, et al. J Biol Chem. 2011 Apr 15;286(15):13626-37. doi: 10.1074/jbc.M110.216820. Epub 2011 Feb 16. J Biol Chem. 2011. PMID: 21325276 Free PMC article.

5

Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy.

Kaumaya PT, Foy KC. Kaumaya PT, et al. Future Oncol. 2012 Aug;8(8):961-87. doi: 10.2217/fon.12.95. Future Oncol. 2012. PMID: 22894670 Free PMC article. Review.

6

Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways.

Vicari D, Foy KC, Liotta EM, Kaumaya PT. Vicari D, et al. J Biol Chem. 2011 Apr 15;286(15):13612-25. doi: 10.1074/jbc.M110.216812. Epub 2011 Feb 14. J Biol Chem. 2011. PMID: 21321115 Free PMC article.

7

Immunotherapy with HER-2 and VEGF peptide mimics plus metronomic paclitaxel causes superior antineoplastic effects in transplantable and transgenic mouse models of human breast cancer.

Foy KC, Miller MJ, Moldovan N, Bozanovic T, Carson WE 3rd, Kaumaya PT. Foy KC, et al. Oncoimmunology. 2012 Oct 1;1(7):1004-1016. doi: 10.4161/onci.21057. Oncoimmunology. 2012. PMID: 23170249 Free PMC article.

8

Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo.

Foy KC, Miller MJ, Moldovan N, Carson WE 3rd, Kaumaya PT. Foy KC, et al. Oncoimmunology. 2012 Oct 1;1(7):1048-1060. doi: 10.4161/onci.20708. Oncoimmunology. 2012. PMID: 23170253 Free PMC article.

9

Insulin-like growth factor-1 receptor signaling increases the invasive potential of human epidermal growth factor receptor 2-overexpressing breast cancer cells via Src-focal adhesion kinase and forkhead box protein M1.

Sanabria-Figueroa E, Donnelly SM, Foy KC, Buss MC, Castellino RC, Paplomata E, Taliaferro-Smith L, Kaumaya PT, Nahta R. Sanabria-Figueroa E, et al. Mol Pharmacol. 2015 Feb;87(2):150-61. doi: 10.1124/mol.114.095380. Epub 2014 Nov 12. Mol Pharmacol. 2015. PMID: 25391374 Free PMC article.

10

HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells.

Miller MJ, Foy KC, Overholser JP, Nahta R, Kaumaya PT. Miller MJ, et al. Oncoimmunology. 2014 Dec 21;3(11):e956012. doi: 10.4161/21624011.2014.956012. eCollection 2014 Nov. Oncoimmunology. 2014. PMID: 25941588 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

108 results

Search Page